Juan Jesús
Cruz Hernández
Hospital Universitario de Salamanca
Salamanca, EspañaPublications in collaboration with researchers from Hospital Universitario de Salamanca (176)
2024
-
Diagnóstico nosológico y de extensión. Factores pronósticos
Oncología clínica (Arán Ediciones), pp. 59-71
-
Epidemiología del cáncer. Factores de riesgo y carcinogénesis
Oncología clínica (Arán Ediciones), pp. 25-42
-
Tumores de origen desconocido
Oncología clínica (Arán Ediciones), pp. 407-418
2023
-
Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis
Chinese Clinical Oncology, Vol. 12, Núm. 6
-
Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk
Cells, Vol. 12, Núm. 15
-
Multimodal Physical Exercise and Functional Rehabilitation Program in Oncological Patients with Cancer-Related Fatigue—A Randomized Clinical Trial
International Journal of Environmental Research and Public Health, Vol. 20, Núm. 6
-
Telomere Length as a New Risk Marker of Early-Onset Colorectal Cancer
International Journal of Molecular Sciences, Vol. 24, Núm. 4
2022
-
Acute esophageal necrosis induced by immune checkpoint inhibitors
Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 3, pp. 182-183
-
Cardiac magnetic resonance to detect different patterns of myocardial injury in patients receiving immune checkpoint inhibitors
Revista Espanola de Cardiologia, Vol. 75, Núm. 3, pp. 266-269
-
Epidemiological Study of Prostate Cancer in the Province of Salamanca (2006-2015)
Archivos espanoles de urologia, Vol. 75, Núm. 7, pp. 630-637
-
Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy
Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88
-
Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis
Biomedicines, Vol. 10, Núm. 2
2021
-
Correction to: SEOM clinical guidelines for the treatment of head and neck cancer (2020) (Clinical and Translational Oncology, (2021), 23, 5, (913-921), 10.1007/s12094-020-02533-1)
Clinical and Translational Oncology
-
Dopamine receptors and the kidney: An overview of health-and pharmacological-targeted implications
Biomolecules, Vol. 11, Núm. 2, pp. 1-16
-
Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors
Life, Vol. 11, Núm. 12
-
Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications
JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169
-
Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 764-772
-
Multimodal physical exercise and functional rehabilitation program in oncological patients with asthenia. study protocol
BMC Nursing, Vol. 20, Núm. 1
-
Resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: A new therapeutic targeting of haematological malignancies
Journal of Clinical Medicine, Vol. 10, Núm. 9
-
The influence of diet and probiotics on the response of solid tumours to immunotherapy: Present and future perspectives
Applied Sciences (Switzerland), Vol. 11, Núm. 18